Renal medullary carcinoma: Molecular, pathological and clinical evidence for ... - UroToday PDF Print
UroTodayTo present the molecular rationale and potential clinical benefit of topoisomerase II (TopoII)-inhibiting therapy for renal medullary carcinoma (RMC),

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.